DJIA 16,514.37 65.12 0.40%
NASDAQ 4,161.46 0.00 0.00%
S&P 500 1,879.55 7.66 0.41%
market minute promo

Dendreon Corp

NASDAQ: DNDN



company name or ticker
Company Photos
(Click to zoom)

6 Reasons Why Bristol-Myers Is A Good Immuno-Oncology Investment For 2014

Medivation Still Prevailing

New data on Medivation's Xtandi still makes it look better than Johnson & Johnson's Zytiga and Dendreon's Provenge.

Could PCT Be NeoStem's Breakout Star?

Apple And Others Should Issue Debt Now

Galena Biopharma: 3 Different Insiders Have Sold Shares This Year

Exelon Shares Brighten Up While Dendreon Dips Nearly 10%

A yearlong exercise intent on proving that value and contrarian investing can be incredibly successful.

Slowing Sales for Johnson & Johnson's Zytiga May Be Good News for Medivation

Sales momentum for Johnson & Johnson's (JNJ) Zytiga is slowing in the United States as competitor Medivation (MDVN) jockeys for position.

Mid-Afternoon Market Update: Markets Recovering Towards the End of the Session as Dendreon Shares In

Mid-Afternoon Market Update: Markets Recovering Towards the End of the Session as Dendreon Shares Inexplicably Fall

Mid-Afternoon Market Update: Markets Recovering Towards the End of the Session as Dendreon Shares In

Mid-Afternoon Market Update: Markets Recovering Towards the End of the Session as Dendreon Shares Inexplicably Fall

Sell Watch: Zeltiq Has Become Over-Speculated

See More Articles...